✦ LIBER ✦

Olfactory bulb in multiple system atrophy

✍ Scribed by Tibor Kovács; Mátyás I. Papp; Nigel J. Cairns; M. Nadeem Khan; Peter L. Lantos

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 833 KB
Volume: 18
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.10466

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Olfactory dysfunction is a characteristic clinical sign in Parkinson's disease (PD); it is also present in multiple system atrophy (MSA). The pathological basis of hyposmia or anosmia in PD is well known: the olfactory bulb (OB) contains numerous Lewy bodies and severe neuronal loss is present in the anterior olfactory nucleus (AON). We established that glial cytoplasmic inclusions (GCIs) are present in all the OBs from MSA cases. Their presence in the OB is diagnostic for MSA. Additionally, neuronal loss is present in the AON in MSA. These pathological changes might be responsible for the olfactory dysfunction seen in MSA. © 2003 Movement Disorder Society

📜 SIMILAR VOLUMES

Survival in multiple system atrophy

✍ Anette Schrag; Gregor K. Wenning; Niall Quinn; Yoav Ben-Shlomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

## Abstract We here report survival in patients with multiple system atrophy (MSA) in a large, prospectively studied group of patients with MSA. Eighty‐five of 100 patients were known to have died. Three patients were rediagnosed as having PD. Twenty‐four patients came to autopsy, which showed MSA

Therapeutic strategies in multiple syste

Therapeutic strategies in multiple system atrophy

✍ Gregor K. Wenning; Felix Geser; Werner Poewe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with

Facial myokymia in multiple system atrop

Facial myokymia in multiple system atrophy

✍ Dr. S. B. Blunt; N. M. Khalil; G. D. Perkin 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB

## Abstract Two patients are described with clinical and neuroimaging features consistent with a diagnosis of multiple system atrophy (MSA). The patients are unusual in that facial myokymia became apparent clinically at some stage in their illness. In each patient, the nature and severity of the in

Olivopontocerebellar pathology in multip

Olivopontocerebellar pathology in multiple system atrophy

✍ G. K. Wenning; F. Tison; L. Elliott; N. P. Quinn; Dr. S. E. Daniel 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 558 KB

## Abstract Olivopontocerebellar atrophy (OPCA) is widely accepted as part of the neuropathological spectrum of multiple system atrophy (MSA). The distribution of affected sites in the olivopontocerebellar (OPC) system and their interrelationship remain poorly understood due to lack of quantitative

Odor maps in the olfactory bulb

✍ Fuqiang Xu; Charles A. Greer; Gordon M. Shepherd 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Multiple system atrophy: An update

✍ Gregor K. Wenning; Felix Geser; Michaela Stampfer-Kountchev; François Tison 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L-d